|Day Low/High||11.90 / 12.64|
|52 Wk Low/High||5.55 / 16.70|
LEXINGTON, Mass., Sept.
Statistically Significant Improvement Across Multiple Symptom and Sign Measures
61% Partial Response Rate of ADX-1612 in Combination with Platinum Therapy
Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018
LEXINGTON, Mass., Aug.
LEXINGTON, Mass., July 31, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
LEXINGTON, Mass., July 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.
LEXINGTON, Mass., July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.
Expanded Pipeline Features Distinct Mechanisms of Action Across Five Product Candidates
LEXINGTON, Mass., June 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.
LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.
Data Demonstrate Statistically and Clinically Significant Activity of Topical Ocular 0.1% Reproxalap Across a Broad Array of Signs and Symptoms
Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.
The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept Pharmaceuticals.
Presentation to Include Additional Data From Aldeyra's Recently Completed Phase IIa Clinical Trial of NS2 in Allergic Conjunctivitis
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.